EPOMAX 2000 UI BT 1

• Treatment of anemia secondary to chronic kidney disease in children and adult patients undergoing hemodialysis and adult patients undergoing peritoneal dialysis.
• Treatment of severe renal anemia accompanied by clinical symptoms in adult patients with renal insufficiency who have not yet started dialysis.
• Treatment of anemia and reduction of transfusion requirements in adult patients undergoing chemotherapy for solid tumors, malignant lymphomas or multiple myelomas, and at risk of transfusion due to their general condition (e.g. cardiovascular status, preexisting anemia at the start of chemotherapy).

EPOMAX may be used to increase autologous blood donations in patients participating in a delayed autologous transfusion program. Use in this indication should take into account the increased risk of thromboembolic events. The treatment is indicated in patients with moderate anemia (Hb: 10 to 13 g/dl or 6.21 to 8.07 mmol/l) without iron deficiency, when there are no or few blood-saving methods available, and when a major scheduled surgery requires large amounts of blood (4 or more units for women and 5 or more units for men).

EPOMAX may be used to reduce exposure to homologous blood transfusions in adult patients without iron deficiency undergoing a major scheduled orthopedic surgery with a presumed high risk of transfusion-related complications. Use should be reserved for patients with moderate anemia (e.g. Hb: 10 to 13 g/dl) who do not have access to a delayed autologous collection program and are expected to have moderate blood loss (900 to 1,800 ml).

EPOMAX is indicated for the treatment of symptomatic anemia (hemoglobin concentration ≤ 10 g/dL) in adults with low or intermediate 1 risk primary myelodysplastic syndromes (MDS) and low serum erythropoietin levels (200 mU/mL).

Good blood management practices should always be applied in the surgical context.